SeekingAlpha · Sep 11, 2026
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow
2026-09-11. The following slide deck was published by Repligen Corporation in conjunction with this event.
RG
NYSE · RGEN
Repligen Corporation
Healthcare · Medical - Instruments & Supplies
$174.73
Up+$0.02 (+0.01%)
Updated Sep 16, 2026, 4:42 PM
SID Score
6.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.1B
- P/E ratio
- 5,229.48
- Dividend yield
- 0.00%
- 52-week range
- $100.99 – $188.73
- Volume
- 891.26K
- Avg. volume
- 934.31K
Price performance
RGEN price history
1M range · 20 trading sessions · Daily adjusted prices
RGEN closed at $174.73 after 20 trading sessions, up 5.16% for the selected period.
- Last close
- $174.73
- Period change
- +5.16%
- Period low
- $164.68
- Period high
- $182.03
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $168.27 | $175.855 | $168.27 | $174.73 | 891.26K |
| Sep 14, 2026 | $166.74 | $168.42 | $162.10 | $168.00 | 514.4K |
| Sep 11, 2026 | $166.72 | $168.06 | $164.02 | $165.18 | 944.56K |
| Sep 10, 2026 | $162.68 | $165.04 | $161.1416 | $164.68 | 955.98K |
| Sep 9, 2026 | $168.53 | $169.52 | $162.46 | $165.05 | 1.08M |
| Sep 8, 2026 | $168.05 | $172.945 | $166.32 | $168.53 | 779.44K |
| Sep 4, 2026 | $167.26 | $169.51 | $165.00 | $167.60 | 806.07K |
| Sep 3, 2026 | $175.53 | $176.13 | $167.54 | $169.61 | 1.33M |
| Sep 2, 2026 | $171.765 | $176.87 | $168.58 | $172.94 | 959.33K |
| Sep 1, 2026 | $180.70 | $182.5692 | $167.42 | $170.02 | 1.41M |
| Aug 31, 2026 | $174.17 | $181.07 | $174.01 | $180.98 | 790.97K |
| Aug 28, 2026 | $179.76 | $181.345 | $175.695 | $176.27 | 818.72K |
| Aug 27, 2026 | $179.90 | $183.09 | $179.14 | $182.03 | 611.9K |
| Aug 26, 2026 | $180.11 | $183.43 | $179.465 | $180.30 | 539.1K |
| Aug 25, 2026 | $181.62 | $185.34 | $178.9812 | $181.69 | 1.14M |
| Aug 24, 2026 | $180.60 | $183.05 | $176.28 | $181.62 | 1.5M |
| Aug 21, 2026 | $179.66 | $182.425 | $175.745 | $181.13 | 1.1M |
| Aug 20, 2026 | $174.61 | $188.73 | $173.135 | $180.29 | 1.59M |
| Aug 19, 2026 | $172.74 | $179.87 | $170.00 | $176.36 | 1.9M |
| Aug 18, 2026 | $168.01 | $168.03 | $164.83 | $166.15 | 462.72K |
Latest RGEN news
The latest Smart Investors Daily articles mentioning RGEN.
Stock researchCompany · Overview
RGEN research
Overview
Company profile and research snapshot.
Company profile
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $171.00
- Implied upside
- —
- Analysts
- 28
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | UBS | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 29, 2026 | JP Morgan | Overweight | — |
| Jul 7, 2026 | Benchmark | Buy | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 9, 2026
3 Reasons to Avoid RGEN and 1 Stock to Buy Instead
Over the past six months, Repligen has been a great trade, beating the S&P 500 by 18.1%. Its stock price has climbed to $168.43, representing a healthy 31.7% increase. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
Yahoo · Sep 9, 2026
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
SeekingAlpha · Sep 9, 2026
Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Repligen Corporation (RGEN) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 1:30 PM EDTCompany ParticipantsOlivier Loeillot - President, CEO...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
